Biosimilar to Infliximab Switch Yields Similar IBD Outcomes (CME/CE)

(MedPage Today) -- No significant changes in clinical remission, and no new safety signals
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news
More News: Remicade | Rheumatology